News Articles for PharmAust

PharmAust has hit a major milestone, signing a landmark deal with US pharmaceutical giant Elanco to develop the company's promising anti-cancer drug “Monepantel”. The deal will see Elanco supply PharmAust with high-grade Monepantel for use in clinical trials in dogs with cancer and in return Pharmaust will grant Elenco an option to negotiate a deal to take Pharmaust's IP to the global market.

ASX-listed biotech PharmAust has successfully identified a revamped formulation of its promising anti-cancer drug “Monepantel”. Perth-based PharmAust says that the reformulated Monepantel will improve the drug's taste and enable the delivery of over 10 times the amount of substance per dose than previously, paving the way for clinical trials ahead of full scale commercialisation.

Perth-based biotech company PharmAust has announced a set of tail wagging results from tests conducted on dogs with cancer who were given PharmAust's promising development drug Monepantel, or MPL, which stabilised the spread of the disease in the animals. 6 of the 7 dogs tested experienced a reduction in tumour size over a two week period when administered with MPL.

PharmAust's acquisition last month of a library of compounds from a major Japanese pharmaceutical company is looking like a shrewd move. Initial tests show some of the newly acquired compounds can kill cancer cells grown in-vitro up to six times more effectively than the parent compound, Monepantel, which is Pharmaust's flagship anti-cancer drug.

ASX-listed biotech PharmAust continues to bolster its IP safeguards around its portfolio of anti-cancer treatments, securing a key patent in the US. The latest patent, which secures PharmAust's IP in the major North American market, relates to the use of a library of cancer fighting compounds owned by Perth-based PharmAust after being developed by Japanese pharma Nihon Nohyaku.

ASX listed PharmAust's wholly owned subsidiary Epichem has been named WA exporter of the year in recognition of the Perth-based company's ongoing excellence in the medicinal chemistry field. Epichem also received the Health and Biotechnology gong at the prestigious West Australian business event and PharmAust are predicting further rapid growth at the subsidiary, forecasting revenues of $4 million for FY18.

ASX-listed biotech PharmAust has hit several key milestones in the development of its promising anti-cancer drug Monepantel, or MPL as it is commonly known. The company says reformulation of the potential breakthrough anti-cancer substance is progressing well, with its Canadian partner, BRI Pharmaceutical Research, achieving long awaited improvements on taste and dosage capacity.

ASX-listed biotech PharmAust has secured a patent in the US relating to the use of its promising anti-cancer drug Monepantel, for the treatment of non-cancerous conditions such as neurodegenerative diseases, diabetes and age-related illnesses. The patent is another move by Perth-based PharmAust to boost its global IP protections and follows the granting of patents in Europe, US, Australia and China.

ASX listed biotech Company PharmAust has made significant progress in reformulating its promising anti-cancer drug Monepantel to improve its taste and deliver increased dosages of the substance in each pill. Monepantel has already shown pleasing results in initial clinical trials as a cancer treatment in humans and canines, with further tests of the drug planned for 2018.

ASX-listed biotech PharmAust has been granted a core patent in Europe relating to the use of “aminoacetonitrile derivatives” as potent kinase inhibitors for the treatment of cancer. The patent is another positive step for Perth-based company in shoring up its global IP protections. It follows the granting of similar patents in key markets including the US, Australia and China.

Perth-listed biotech PharmAust has signed a deal with a leading Japanese chemical company that will give the ASX listed company rights to a library of 50 patents over promising anti-cancer agents. The new patents will complement the development of PharmAust's main anti-cancer drug Monepantel, which has already shown positive results in fighting cancer.

Perth based medical research pioneer Epichem, a wholly owned subsidiary of ASX listed PharmAust, has posted record revenues for FY17 on the back of growth across all of its business divisions. PharmAust said Epichem generated a best-ever revenue result of $3.05m for the 12 months to June, up by 30 per cent when compared to the previous year.

Claremont-based biotech company PharmAust has announced a record year for its synthetic and medicinal chemistry subsidiary, and has flagged further growth in the year ahead.

PharmAust has engaged Canadian pharmaceutical specialist BRI to reformulate its promising anti-cancer drug Monepantel in readiness for more clinical trials and commercialisation. Monepantel has already shown positive outcomes treating cancer and PharmAust are now looking to improve the taste profile and palatability of the drug.

Successful clinical trials have led PharmAust to lock down patents for its promising anti-cancer drug in key markets around the world in rapid succession. Research work has indicated the drug might also be effective in combating non-cancer ailments such as brain disease and diabetes, leading to another non-cancer related patent being secured in Europe this week.

PharmAust has secured a patent for its promising anti-cancer drug in another major market, this week adding Japan to a list that already includes Australia, China and the US. The new protection is the latest in a series of recent patent awards that are clearly impressing the market, with PharmAust stock up almost 50% in the past month.

PharmAust's trials of its promising anti-cancer drug in dogs have produced encouraging early results, reducing the size of tumours in three out of four dogs with no other treatment. The early-stage trials have also shown it will be safe to give dogs significantly higher doses, which could lead to some spectacular results in the next stage of trials.

Perth listed biotech PharmAust, have determined that their promising anti-cancer drug known as MPL might also be useful in the treatment of diabetes, brain disease and age related disorders. The company announced this week they have secured a patent for MPL in Australia relating to the treatment of the three newly targeted illnesses.

ASX listed PharmAust has taken a major step towards safeguarding the intellectual property of its promising anti-cancer drug after being granted a key patent in China. The patent strengthens the Perth-based company's IP protection in a critical world market and provides protection for 16 years, with PharmAust expecting further patents to be issued in coming months.

Dr Richard Hopkins has been appointed chief executive officer of PharmAust.Swapna Keskar has been appointed company secretary of CoAssets.

ASX listed PharmAust has named Dr Richard Hopkins as the company's new chief executive. Hopkins was previously running Perth biotech company Phylogica Limited and will start as PharmAust CEO on March 7.

ASX listed PharmAust's wholly owned subsidiary Epichem has posted a record monthly revenue result for January. Pharmaust is developing a promising anti-cancer drug known as “Monepantel” at the Perth based Epichem facility that also undertakes contract work for some of the worlds leading pharmaceutical companies

ASX listed PharmAust has received a $400,000 rebate from the Federal Government in recognition of their cutting edge research and development program being undertaken at two of the Perth-based company's wholly owned subsidiaries. Pharmaust's new anti-cancer drug, Monepantel, has been powering though human and K9 trials with considerable success.

ASX listed PharmAust has revealed a timetable for the development of its promising anti-cancer drug as the Perth-based company moves ahead with human and canine trials. After pleasing results in Phase I human tests of its “Monepantel” drug, the company is pushing ahead with Phase II canine trials.

Upstart biotech company Pharmaust is getting close to proving up their breakthrough anti-cancer drug in dogs with a second canine patient suffering from late stage cancer recruited last week. The company recently announced that a second dog had started treatment at Sydney's Animal Referral Hospital using PharmAust's reformulated drug known as Monepantel.

The University of Cambridge has begun a second phase of canine trials of PharmAust's promising anti-cancer drug, taking it a step closer to widespread availability for pet owners. The trial will also provide information on the potential for the Perth-based company's new drug as a breakthrough cancer treatment for humans.

ASX listed PharmAust subsidiary Epichem has been elevated to a select group of biotech companies that have achieved ISO 9001:2015, an internationally recognised certification for quality, continual improvement and customer focus. Epichem unertakes biotech research for some of the world's largest pharmaceutical companies in Perth.

ASX listed PharmAust has taken the next significant step in the development of its exciting canine cancer drug known as Monepantel or MPL. The company this week announced that it had added two new locations to its Phase 2 trials in Australia, one at the Animal Referral Hospital at Homebush, NSW and the other at Queensland Veterinary Specialists in Brisbane.

ASX listed biotech company PharmAust today announced that a leading veterinary specialist would conduct more canine trials with its promising anti-cancer drug "MP"L. NSW-based dog cancer specialist, Dr Angela Frimberger, will evaluate MPL either as a monotherapy or in conjunction with chemotherapy in dogs that have not responded to standard cancer treatments.

ASX listed cancer drug hopeful Pharmaust have secured additional IP rights to their highly promising anti-cancer drug Monepantel by partially trading off rights to another project under their control. Under the new deal, Pharmaust will receive the remainder of the IP rights to Monepantel that were never transferred to them by the University of NSW.

Anti cancer specialist drug developer Pharmaust, has successfully altered the taste of their promising new anti-cancer drug known as Monepantel to make it taste better on the eve of a new trial of the drug in dogs. The trial will commence immediately at The University of Cambridge who were responsible for inventing the jet engine and identifying the structure of DNA.

ASX listed biotech PharmAust, is rapidly making its mark on the anti-cancer drug industry with its promising ant-cancer drug known as “MPL”. The company recently announced they would partner up with the same UK university that was first responsible for splitting the atom and the discovery of stem cells in their upcoming phase 2 trial of MPL in canines.

Perth based Pharmaust has received a $250k Federal grant to conduct a research program into a little known illness known as Leishmaniasis disease. They will work in partnership with a Swiss not for profit who will retain rights to any drugs produced for humans with Pharmaust retaining the rights to any drugs developed that cure Leishmaniasis in animals.

Anti-Cancer drug hopeful Pharmaust will be fully funded to enter into Phase 2 human trials after well established New York investment bank Joseph Gunnar and Co agreed to underwrite the company's next capital raise which will be done in the USA. Phase 2 trials are expected to start in a couple of months after their anti-Cancer drug is reformulated to make it more palatable.

Respected Florida based US research house Redchip, has re-rated ASX listed cancer drug hopeful Pharmaust at 35c a share, almost triple its current share price. The total Net Present Value calculated by Redchip for Pharmaust out to 2030 is $56.5m, considerably higher than Pharmaust's current market cap that hovers between $10m and around $12m.

Leading ASX listed Cancer drug specialist Pharmaust, are in discussions with a UK-based clinical oncologist to evaluate their anti-cancer drug known as Monepantel in patients with oesophageal cancer. The trials, which will analyse the effect of Monepantel on patient's tumours are designed to provide short term feedback on the efficacy of the drug.

Epichem, a wholly owned subsidiary of ASX listed biotech hopeful Pharmaust, has reached the pinnacle of its 13 year existence with the opening of its new state of the art chemistry lab in Technology Park, Bentley. The new lab which is double the size of the old one previously operated on site at Murdoch University, cost $1.6m and boasts a serious brains trust of 13 PHD's amongst its 18 staff.

Perth based listed cancer drug hopeful Pharmaust, has received a $546 000 Government windfall from the Research and Development Rebate Scheme. Under the scheme, eligible Australian companies that are undertaking approved research and development activities can claim up to 43.5% of their expenditure back from the Federal Government.

Anti-cancer drug hopeful Pharmaust has moved to overcome a limitation discovered in its promising cancer drug known as Monepantel during recent phase 1 human trials. Juniper Pharmaceuticals have been appointed to reformulate the company's Monepantel drug with the goal being to improve its taste and palatability.

PharmAust Limited has announced that its wholly-owned subsidiary Epichem Pty Ltd has been awarded a two-year extension to its current contract with Drugs for Neglected Diseases Initiative (DNDi)